# US 11,078,263 B2 · Fc γ RIII binding fibronectin type III domains, their conjugates and multispecific molecules comprising them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,263 B2
- Document ID: US11078263B2
- Status: Granted
- Kind: B2
- Application number: 16/111,360
- Filed: 2018-08-24
- Published: 2019-02-28
- Granted: 2021-08-03
- Earliest claimed: 2017-08-25
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Mark Chiu; Brian Whitaker; Di Zhang
- Web page: https://patentgrep.com/patent/US11078263B2

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C07K 16/18: against material from animals or humans
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C07K 14/435: from animals; from humans
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

FN3 domains that specifically bind FcγRII, their conjugates and antibody fusions, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them.

## Claims

### Claim 1

A method of enhancing antibody dependent cellular phagocytosis (ADCP) activity of a polypeptide, comprising:
conjugating a FcγRII binding fibronectin type III (FN3) domain comprising the sequence of SEQ ID NO: 16, 17, 18, 19, 20, 21, or 22 to the polypeptide to thereby enhance the ADCP activity of the polypeptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the FN3 domain comprises the sequence of SEQ ID NO: 16.

### Claim 3 (depends on 1)

The method of claim 1, wherein the FN3 domain comprises the sequence of SEQ ID NO: 17.

### Claim 4 (depends on 1)

The method of claim 1, wherein the FN3 domain comprises the sequence of SEQ ID NO: 18.

### Claim 5 (depends on 1)

The method of claim 1, wherein the FN3 domain comprises the sequence of SEQ ID NO: 19.

### Claim 6 (depends on 1)

The method of claim 1, wherein the FN3 domain comprises the sequence of SEQ ID NO: 20.

### Claim 7 (depends on 1)

The method of claim 1, wherein the FN3 domain comprises the sequence of SEQ ID NO: 21.

### Claim 8 (depends on 1)

The method of claim 1, wherein the FN3 domain comprises the sequence of SEQ ID NO: 22.

### Claim 9 (depends on 1)

The method of claim 1, wherein the polypeptide is an antibody.

### Claim 10 (depends on 1)

The method of claim 1, wherein the FN3 domain is conjugated to the N-terminus of the polypeptide.

### Claim 11 (depends on 1)

The method of claim 1, wherein the FN3 domain is conjugated to the C-terminus of the polypeptide.

### Claim 12 (depends on 1)

The method of claim 1, wherein the conjugating comprises cloning the FN3 domain and the polypeptide into a vector and expressing a FN3-polypeptide conjugate.

### Claim 13 (depends on 1)

The method of claim 1, wherein the conjugating comprises chemically coupling the FN3 domain and the polypeptide.